Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 476,948 shares of the specialty pharmaceutical company’s stock after buying an additional 35,722 shares during the quarter. Vanguard Group Inc. owned about 4.10% of ANI Pharmaceuticals worth $22,322,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its position in shares of ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 664 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of ANI Pharmaceuticals by 132.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 2,390 shares during the last quarter. Stevens Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $207,000. Thrivent Financial For Lutherans lifted its position in shares of ANI Pharmaceuticals by 5.1% during the first quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 220 shares during the last quarter. Finally, Intrust Bank NA lifted its position in shares of ANI Pharmaceuticals by 11.8% during the second quarter. Intrust Bank NA now owns 5,051 shares of the specialty pharmaceutical company’s stock valued at $236,000 after buying an additional 535 shares during the last quarter. 56.48% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on ANIP shares. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Canaccord Genuity initiated coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They issued a “buy” rating and a $60.00 price objective for the company. BidaskClub lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $68.25.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) opened at $61.83 on Tuesday. The company has a market cap of $721.32, a P/E ratio of 18.48 and a beta of 2.85. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals, Inc. has a 1 year low of $42.23 and a 1 year high of $65.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to analyst estimates of $48.12 million. During the same period last year, the firm posted $1.09 EPS. ANI Pharmaceuticals’s revenue was up 25.0% on a year-over-year basis. research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.59 earnings per share for the current fiscal year.

WARNING: “Vanguard Group Inc. Grows Position in ANI Pharmaceuticals, Inc. (ANIP)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/vanguard-group-inc-grows-position-in-ani-pharmaceuticals-inc-anip/1701772.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.